The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features Todd Michaels, President and CEO of Correlate Infrastructure Partners Inc. (OTCQB: CIPI), a technology-enabled energy optimization and clean-energy solutions provider.

To begin the interview, Michaels provided an introduction to Correlate Infrastructure Partners and its business model.

“Correlate Infrastructure Partners is the parent company for a series of technology and fulfillment subsidiaries in the clean energy space. Solar Site Design and Correlate are some of our commercial brands, and we’re in the process of adding technologies and companies to our portfolio,” Michaels said. “We’re effectively looking at how to scale the business through technology enablement and automation, integrate and verticalize sales, develop projects and, ultimately, fulfill those projects on facilities in North America.”

Bell2Bell’s latest podcast features Todd Michaels, President and CEO of Correlate Infrastructure Partners Inc. (OTCQB: CIPI), a technology-enabled energy optimization and clean-energy solutions provider.

To begin the interview, Michaels provided an introduction to Correlate Infrastructure Partners and its business model.

“Correlate Infrastructure Partners is the parent company for a series of technology and fulfillment subsidiaries in the clean energy space. Solar Site Design and Correlate are some of our commercial brands, and we’re in the process of adding technologies and companies to our portfolio,” Michaels said. “We’re effectively looking at how to scale the business through technology enablement and automation, integrate and verticalize sales, develop projects and, ultimately, fulfill those projects on facilities in North America.”

Bell2Bell’s latest podcast features Brad Damm, VP of Sales and Marketing for Cub Crafters Inc. (“CubCrafters”), an OEM aircraft manufacturer.

To begin the interview, Damm provided an introduction to CubCrafters’ business model and operating markets.

“CubCrafters is an aircraft manufacturer located in Washington State, and we build bush planes. These are the type of planes that you would see on floats or pontoons in the Alaska backcountry,” Damm said. “Oftentimes, they’re equipped with big tires, called tundra tires, so they can go off-airport. We can land on anything from a cow pasture to a ridgetop. These are planes that can do about 80-90% of what a helicopter can do at about a tenth of the cost.”

Bell2Bell’s latest podcast features Brad Damm, VP of Sales and Marketing for Cub Crafters Inc. (“CubCrafters”), an OEM aircraft manufacturer.

To begin the interview, Damm provided an introduction to CubCrafters’ business model and operating markets.

“CubCrafters is an aircraft manufacturer located in Washington State, and we build bush planes. These are the type of planes that you would see on floats or pontoons in the Alaska backcountry,” Damm said. “Oftentimes, they’re equipped with big tires, called tundra tires, so they can go off-airport. We can land on anything from a cow pasture to a ridgetop. These are planes that can do about 80-90% of what a helicopter can do at about a tenth of the cost.”

Bell2Bell’s latest podcast features the return of Chase Edgelow, Co-Founder and CEO of EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas infrastructure platform.

Throughout the interview, Edgelow discussed EverGen’s recent corporate milestones, beginning with the company’s May acquisition of a 50% interest in Project Radius.

“Project Radius is a mark of our expansion across Canada, continuing to build our renewable natural gas (RNG) platform with three large-scale RNG projects that have the capability of producing almost two million gigajoules per year once they are up-and-running,” Edgelow said. “Renewable natural gas, in Canada and the U.S., is a market that’s really starting to pick up steam. The gas utilities on both sides of Canada – the West Coast and Quebec – have both set targets of 15-20% of their volume to come from RNG or renewable products by 2030.”

Bell2Bell’s latest podcast features the return of Chase Edgelow, Co-Founder and CEO of EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas infrastructure platform.

Throughout the interview, Edgelow discussed EverGen’s recent corporate milestones, beginning with the company’s May acquisition of a 50% interest in Project Radius.

“Project Radius is a mark of our expansion across Canada, continuing to build our renewable natural gas (RNG) platform with three large-scale RNG projects that have the capability of producing almost two million gigajoules per year once they are up-and-running,” Edgelow said. “Renewable natural gas, in Canada and the U.S., is a market that’s really starting to pick up steam. The gas utilities on both sides of Canada – the West Coast and Quebec – have both set targets of 15-20% of their volume to come from RNG or renewable products by 2030.”

Bell2Bell’s latest podcast features Dr. Faz Chowdhury, Chairman and CEO of Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing and commercializing affordable diagnostic and digital tools for chronic disease management.

Throughout the interview, Chowdhury provided an introduction to Nemaura Medical and discussed its business model.

“Nemaura Medical was founded just over a decade back, and, over that period of time, we’ve been focused on developing a body-worn sensor designed for both consumer and medical applications in the diabetes space,” Chowdhury said. “We use the sensor to look at insight you otherwise could not gauge just by using existing technologies – taking a drop of blood and putting it on a strip, for example… It has taken us a good part of the 10 years to develop the technical aspects of the product, get the clinical studies done and get regulatory approvals in Europe. Now, we are already commercializing product in the UK, and we are looking at launching in other places in Europe and then into the U.S.”

Bell2Bell’s latest podcast features Dr. Faz Chowdhury, Chairman and CEO of Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing and commercializing affordable diagnostic and digital tools for chronic disease management.

Throughout the interview, Chowdhury provided an introduction to Nemaura Medical and discussed its business model.

“Nemaura Medical was founded just over a decade back, and, over that period of time, we’ve been focused on developing a body-worn sensor designed for both consumer and medical applications in the diabetes space,” Chowdhury said. “We use the sensor to look at insight you otherwise could not gauge just by using existing technologies – taking a drop of blood and putting it on a strip, for example… It has taken us a good part of the 10 years to develop the technical aspects of the product, get the clinical studies done and get regulatory approvals in Europe. Now, we are already commercializing product in the UK, and we are looking at launching in other places in Europe and then into the U.S.”

Bell2Bell’s latest podcast features Amro Albanna, Co-Founder, Chairman and CEO of Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company.

Throughout the interview, Albanna provided an introduction to Aditxt and discussed its business model.

“We are a biotech innovation company, and our focus is on immune diseases. The reality is that immune diseases are caused either by someone having too little immune response or too much immune response,” Albanna said. “When you have too little immune response and you’re dealing with COVID-19, we all understand the story, and that applies to other viral diseases. Too much immunity is also not a good thing. When you have too much immune response, you get into the area of autoimmune diseases – multiple sclerosis, type I diabetes, and psoriasis. These all happen when our immune system begins to overreact and attack our own tissues and cells.”

Join IBN’s Stuart Smith and Amro Albanna to learn more about the company’s seasoned management team, as well as its recent milestones and goals for the balance of 2022 and beyond.

Bell2Bell’s latest podcast features Amro Albanna, Co-Founder, Chairman and CEO of Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company.

Throughout the interview, Albanna provided an introduction to Aditxt and discussed its business model.

“We are a biotech innovation company, and our focus is on immune diseases. The reality is that immune diseases are caused either by someone having too little immune response or too much immune response,” Albanna said. “When you have too little immune response and you’re dealing with COVID-19, we all understand the story, and that applies to other viral diseases. Too much immunity is also not a good thing. When you have too much immune response, you get into the area of autoimmune diseases – multiple sclerosis, type I diabetes, and psoriasis. These all happen when our immune system begins to overreact and attack our own tissues and cells.”

Join IBN’s Stuart Smith and Amro Albanna to learn more about the company’s seasoned management team, as well as its recent milestones and goals for the balance of 2022 and beyond.